Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 14

Results For "disease"

2056 News Found

Hyderabad based CSIR institutes playing pivotal role in drug discovery and genetic diagnostics: Dr. Jitendra Singh
Startup | April 07, 2025

Hyderabad based CSIR institutes playing pivotal role in drug discovery and genetic diagnostics: Dr. Jitendra Singh

In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025


Delhi becomes 35th state/UT to implement AB PM-JAY
Policy | April 07, 2025

Delhi becomes 35th state/UT to implement AB PM-JAY

Nadda noted that on the basis of economic caste census, 50 crore people were brought under this scheme


Lupin acquires UK-based Renascience Pharma for £12.3 million
News | April 04, 2025

Lupin acquires UK-based Renascience Pharma for £12.3 million

The portfolio includes branded injectable cephalosporines for infectious diseases


Enhertu approved in EU in post-ET breast cancer
Drug Approval | April 04, 2025

Enhertu approved in EU in post-ET breast cancer

Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease


Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025
News | April 04, 2025

Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study


Wacker collaborates with RNAV8 Bio to enhance mRNA therapeutics development
Biotech | April 04, 2025

Wacker collaborates with RNAV8 Bio to enhance mRNA therapeutics development

This collaboration positions WACKER and RNAV8 as premium mRNA service providers


AstraZeneca’s Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer
Drug Approval | April 04, 2025

AstraZeneca’s Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone


Alembic announces USFDA final approval for Pantoprazole Sodium for Injection, 40 mg/vial
Drug Approval | April 03, 2025

Alembic announces USFDA final approval for Pantoprazole Sodium for Injection, 40 mg/vial

Pantoprazole Sodium for Injection, 40 mg/vial (Single-Dose Vial) have an estimated market size of US$ 48 million for twelve months ending December 2024 according to IQVIA


Akums launches Ripasudil + Timolol combination for glaucoma treatment
News | April 01, 2025

Akums launches Ripasudil + Timolol combination for glaucoma treatment

The new combination therapy offers a dual mechanism of action for superior intraocular pressure control


Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD
News | March 29, 2025

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD

Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)